These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31937163)

  • 1. Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections.
    Logue J; Crozier I; Jahrling PB; Kuhn JH
    Expert Rev Vaccines; 2020 Jan; 19(1):85-103. PubMed ID: 31937163
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccination of travelers: how far have we come and where are we going?
    Chen LH; Hill DR; Wilder-Smith A
    Expert Rev Vaccines; 2011 Nov; 10(11):1609-20. PubMed ID: 22043959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccines: a review.
    Lewis PJ; Babiuk LA
    Adv Virus Res; 1999; 54():129-88. PubMed ID: 10547676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic DNA vaccine strategies against persistent viral infections.
    Villarreal DO; Talbott KT; Choo DK; Shedlock DJ; Weiner DB
    Expert Rev Vaccines; 2013 May; 12(5):537-54. PubMed ID: 23659301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial overview: Preventive and therapeutic vaccines: Vaccination against viral disease - current advances and challenges.
    Rappuoli R; Sutter G
    Curr Opin Virol; 2017 Apr; 23():vi-viii. PubMed ID: 28622999
    [No Abstract]   [Full Text] [Related]  

  • 7. Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Scholte FEM; Goldsmith CS; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2019 Sep; 220(8):1281-1289. PubMed ID: 31152662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral vectors as vaccine platforms: deployment in sight.
    Rollier CS; Reyes-Sandoval A; Cottingham MG; Ewer K; Hill AV
    Curr Opin Immunol; 2011 Jun; 23(3):377-82. PubMed ID: 21514130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viruses - from pathogens to vaccine carriers.
    Small JC; Ertl HC
    Curr Opin Virol; 2011 Oct; 1(4):241-5. PubMed ID: 22003377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.
    Fathi A; Dahlke C; Addo MM
    Hum Vaccin Immunother; 2019; 15(10):2269-2285. PubMed ID: 31368826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
    Barrett PN; Terpening SJ; Snow D; Cobb RR; Kistner O
    Expert Rev Vaccines; 2017 Sep; 16(9):883-894. PubMed ID: 28724343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel vaccine strategies against emerging viruses.
    García-Sastre A; Mena I
    Curr Opin Virol; 2013 Apr; 3(2):210-6. PubMed ID: 23477832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling.
    Bowick GC; McAuley AJ
    Bioeng Bugs; 2011; 2(3):129-35. PubMed ID: 21637006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya.
    Gerke C; Frantz PN; Ramsauer K; Tangy F
    Expert Rev Vaccines; 2019 Apr; 18(4):393-403. PubMed ID: 30601074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to induce broadly protective antibody responses to viral glycoproteins.
    Krammer F
    Expert Rev Vaccines; 2017 May; 16(5):503-513. PubMed ID: 28277797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postexposure Effects of Vaccines on Infectious Diseases.
    Gallagher T; Lipsitch M
    Epidemiol Rev; 2019 Jan; 41(1):13-27. PubMed ID: 31680134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging respiratory viruses: challenges and vaccine strategies.
    Gillim-Ross L; Subbarao K
    Clin Microbiol Rev; 2006 Oct; 19(4):614-36. PubMed ID: 17041137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in respiratory virus vaccine development.
    Schmidt AC
    Semin Respir Crit Care Med; 2011 Aug; 32(4):527-40. PubMed ID: 21858754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines against dengue virus.
    Woodland DL
    Viral Immunol; 2015 Mar; 28(2):75. PubMed ID: 25689610
    [No Abstract]   [Full Text] [Related]  

  • 20. Animal vaccination and the evolution of viral pathogens.
    Schat KA; Baranowski E
    Rev Sci Tech; 2007 Aug; 26(2):327-38. PubMed ID: 17892155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.